chr19-45407107-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_012099.3(POLR1G):āc.36C>Gā(p.Phe12Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00184 in 1,598,288 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00098 ( 0 hom., cov: 32)
Exomes š: 0.0019 ( 1 hom. )
Consequence
POLR1G
NM_012099.3 missense
NM_012099.3 missense
Scores
2
4
13
Clinical Significance
Conservation
PhyloP100: 0.796
Genes affected
POLR1G (HGNC:24219): (RNA polymerase I subunit G) Enables RNA binding activity. Predicted to be involved in transmembrane receptor protein tyrosine kinase signaling pathway. Predicted to act upstream of or within rRNA transcription. Located in cytosol; mitochondrion; and nuclear lumen. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.09372342).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLR1G | NM_012099.3 | c.36C>G | p.Phe12Leu | missense_variant | 2/3 | ENST00000309424.8 | NP_036231.1 | |
POLR1G | NM_001297590.3 | c.42C>G | p.Phe14Leu | missense_variant | 2/3 | NP_001284519.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLR1G | ENST00000309424.8 | c.36C>G | p.Phe12Leu | missense_variant | 2/3 | 1 | NM_012099.3 | ENSP00000310966 | P4 | |
POLR1G | ENST00000589804.1 | c.42C>G | p.Phe14Leu | missense_variant | 2/3 | 1 | ENSP00000465099 | A2 | ||
POLR1G | ENST00000592852.1 | c.-499C>G | 5_prime_UTR_variant | 1/2 | 2 | ENSP00000467771 | ||||
POLR1G | ENST00000590794.1 | c.20+389C>G | intron_variant | 5 | ENSP00000466503 |
Frequencies
GnomAD3 genomes AF: 0.000986 AC: 150AN: 152168Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
150
AN:
152168
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00115 AC: 271AN: 234758Hom.: 0 AF XY: 0.00114 AC XY: 146AN XY: 127636
GnomAD3 exomes
AF:
AC:
271
AN:
234758
Hom.:
AF XY:
AC XY:
146
AN XY:
127636
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00193 AC: 2786AN: 1446002Hom.: 1 Cov.: 31 AF XY: 0.00184 AC XY: 1327AN XY: 719630
GnomAD4 exome
AF:
AC:
2786
AN:
1446002
Hom.:
Cov.:
31
AF XY:
AC XY:
1327
AN XY:
719630
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000985 AC: 150AN: 152286Hom.: 0 Cov.: 32 AF XY: 0.000994 AC XY: 74AN XY: 74468
GnomAD4 genome
AF:
AC:
150
AN:
152286
Hom.:
Cov.:
32
AF XY:
AC XY:
74
AN XY:
74468
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
12
ALSPAC
AF:
AC:
9
ESP6500AA
AF:
AC:
3
ESP6500EA
AF:
AC:
16
ExAC
AF:
AC:
132
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 06, 2023 | The c.36C>G (p.F12L) alteration is located in exon 2 (coding exon 2) of the CD3EAP gene. This alteration results from a C to G substitution at nucleotide position 36, causing the phenylalanine (F) at amino acid position 12 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;.
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Benign
D
LIST_S2
Benign
T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Benign
L;.
MutationTaster
Benign
N;N
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;.
REVEL
Benign
Sift
Uncertain
D;.
Sift4G
Benign
T;T
Polyphen
D;D
Vest4
MutPred
Loss of glycosylation at S13 (P = 0.1601);.;
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at